Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
As previously disclosed, under the terms of the Agreement, Optime has acted as a specialty pharmacy distributor of Korlym and t...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintain...
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week ...
Throughout the last three months, 4 analysts have evaluated Corcept Therapeutics (NASDAQ: CORT), offering a diverse set of opin...
Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ: CORT) with a Buy and maintains $140 price targ...
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medicat...
Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target fr...
FDA assigns a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026Corcept Therapeutics Incorporated (NASDAQ:CORT), a co...
